Ranirestat has a stronger inhibitory activity on aldose reductase and suppresses inflammatory reactions in high glucose–exposed endothelial cells

Objective: Under diabetic conditions, glucose is converted to sorbitol via aldose reductase, whose process could contribute to diabetic vascular complications. However, effects of aldose reductase inhibitors are modest in diabetic patients. This may be attributed to weak inhibitory activity of aldose reductase inhibitors. We compared effects of ranirestat on endothelial cell damage with those of epalrestat. Materials and methods: Intracellular formations of sorbitol and superoxide were measured by liquid chromatography–mass spectrometry–mass spectrometry and dihydroethidium staining, respectively. Vascular cell adhesion molecule-1 gene expression was analysed by reverse transcription polymerase chain reaction. THP-1 cell adhesion to human umbilical vein endothelial cells was evaluated using a fluorescent probe. Results: High glucose significantly increased sorbitol levels, superoxide generation and vascular cell adhesion molecule-1 mRNA levels in, and THP-1 cell adhesion to, human umbilical vein endothelial cells, all of which were prevented by 500 nM ranirestat, but not epalrestat except for superoxide production. Conclusion: Our present results suggest that ranirestat has a stronger inhibitory activity on aldose reductase than epalrestat and suppresses inflammatory reactions in high glucose–exposed human umbilical vein endothelial cells.

[1]  B. S. Sekhon,et al.  Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases. , 2015, Mini reviews in medicinal chemistry.

[2]  S. Yamagishi,et al.  Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression , 2014, Cardiovascular Diabetology.

[3]  R. Kawamori,et al.  Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[4]  K. Martin,et al.  Aldose Reductase, Oxidative Stress, and Diabetic Mellitus , 2012, Front. Pharmacol..

[5]  Ravichandran Ramasamy,et al.  Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. , 2010, Circulation research.

[6]  P. Bennett,et al.  Quantitative determination of endogenous sorbitol and fructose in human nerve tissues by atmospheric-pressure chemical ionization liquid chromatography/tandem mass spectrometry. , 2005, Rapid communications in mass spectrometry : RCM.

[7]  T. Imaizumi,et al.  Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. , 2005, Current pharmaceutical design.

[8]  T. Jomori,et al.  Sorbitol dehydrogenase overexpression potentiates glucose toxicity to cultured retinal pericytes. , 2002, Biochemical and biophysical research communications.

[9]  M. Itoh,et al.  Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells: effect of antidiabetic medicines. , 2002, Journal of diabetes and its complications.

[10]  K. Kuboki,et al.  Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. , 2001, Journal of diabetes and its complications.

[11]  K. Yoshida,et al.  Stereospecific interaction of a novel spirosuccinimide type aldose reductase inhibitor, AS-3201, with aldose reductase. , 2001, Biochemistry.

[12]  T. Wakatsuki,et al.  Expression of intercellular adhesion molecule-1 induced by high glucose concentrations in human aortic endothelial cells. , 2001, Life sciences.